GlassScriptPhysician profile
Paul S Lemberg
NPI 1346227691
$881.13
in general payments reported to CMS, 2019-2025
15 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $204 · 2021: $29.67 · 2022: $159 · 2023: $22.20 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $139.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $206.51 | 2019-2021 | |
| Genzyme Corporation | $178.84 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $124.74 | 2022 | |
| Acera Surgical, INC. | $117.58 | 2025 | Restrata Wound Matrix |
| Optinose US, INC. | $78.30 | 2019-2020 | |
| Glaxosmithkline, LLC. | $34.46 | 2022 | |
| Intersect Ent, INC. | $34.45 | 2019-2020 | |
| Covidien LP | $22.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.52 | 2019 | |
| Cook Medical LLC | $12.54 | 2019 | |
| Phadia US INC. | $11.66 | 2020 | |
| Kaleo, INC. | $11.59 | 2019 | |
| Aytu Biopharma, INC. | $11.21 | 2019 | |
| Alk-Abello, INC | $11.04 | 2020 | |
| Glenmark Therapeutics INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lemberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.